These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1356678)

  • 1. Regulation of in vitro anti-DNA antibody production by a novel disease modifying anti-rheumatic drug, Lobenzarit.
    Hirohata S
    Clin Exp Rheumatol; 1992; 10(4):357-63. PubMed ID: 1356678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of B cell function by lobenzarit, a novel disease-modifying antirheumatic drug.
    Hirohata S; Shinohara S; Inoue T; Miyamoto T; Lipsky PE
    Arthritis Rheum; 1992 Feb; 35(2):168-75. PubMed ID: 1734906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of B cell function by bucillamine, a novel disease-modifying antirheumatic drug.
    Hirohata S; Lipsky PE
    Clin Immunol Immunopathol; 1993 Jan; 66(1):43-51. PubMed ID: 8440072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immunomodulating anti-rheumatic drug, lobenzarit disodium (CCA): inhibition of polyclonal B-cell activation and prevention of autoimmune disease in MRL/Mp-lpr/lpr mice.
    Mihara M; Nakano T; Ohsugi Y
    Clin Immunol Immunopathol; 1987 Dec; 45(3):366-74. PubMed ID: 3500002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lobenzarit disodium (CCA) inhibits in vitro immunoglobulin production via direct interaction with B lymphocytes.
    Takeda Y; Urakawa K; Sakamoto A; Nakano T; Sugawara Y; Ohsugi Y; Morita M; Kasahara T
    Chem Pharm Bull (Tokyo); 1992 Jan; 40(1):177-81. PubMed ID: 1576670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell regulation of in vitro IgM-rheumatoid factor production by normal human B cells. Differential effects of stimulation with immobilized monoclonal antibodies to CD3 and Staphylococcus aureus.
    Hirohata S; Inoue T; Miyamoto T
    Arerugi; 1990 Feb; 39(2 Pt 1):82-9. PubMed ID: 2141251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency analysis of human peripheral blood B cells producing autoantibodies: differential activation requirements of precursors for B cells producing IgM-RF and anti-DNA antibody.
    Hirohata S; Inoue T; Ito K
    Cell Immunol; 1991 Dec; 138(2):445-55. PubMed ID: 1834351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of human B cell activation by a novel nonsteroidal anti-inflammatory drug, indometacin famesil.
    Hirohata S; Yanagida T; Kawai M; Kikuchi H
    Immunopharmacology; 1999 Nov; 44(3):245-54. PubMed ID: 10598881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency analysis of human peripheral blood B cells producing IgM-rheumatoid factor. Differential effects of stimulation with monoclonal antibodies to CD3 and Staphylococcus aureus.
    Hirohata S; Inoue T; Miyamoto T
    J Immunol; 1990 Sep; 145(6):1681-6. PubMed ID: 2144005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of human B cell responsiveness by CD4+ T cells does not involve CD95-CD95 ligand interactions.
    Hirohata S
    Cell Immunol; 1997 Nov; 181(2):182-91. PubMed ID: 9398405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunopharmacological study of CCA (Lobenzarit disodium), an anti-arthritis agent--I. Abrogation of IL 1 secretion by LPS-stimulated human monocytes and induction of gamma-interferon production with CCA.
    Fujimoto M; Sugawara I; Kimoto M; Ishizaka S; Tsujii T
    Int J Immunopharmacol; 1986; 8(3):323-8. PubMed ID: 3089953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative inhibitory effects of bucillamine and D-penicillamine on the function of human B cells and T cells.
    Hirohata S; Lipsky PE
    Arthritis Rheum; 1994 Jun; 37(6):942-50. PubMed ID: 8003068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of systemic lupus erythematosus with lobenzarit: an open clinical trial.
    Hirohata S; Ohnishi K; Sagawa A
    Clin Exp Rheumatol; 1994; 12(3):261-5. PubMed ID: 8070158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of expression of cyclin A in human B cells by an immunosuppressant mizoribine.
    Hirohata S; Yanagida T
    J Immunol; 1995 Dec; 155(11):5175-83. PubMed ID: 7594527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of interferon-alpha on human B cell responsiveness: biphasic effects in cultures stimulated with Staphylococcus aureus.
    Oka H; Hirohata S; Inoue T; Ito K
    Cell Immunol; 1992 Feb; 139(2):478-92. PubMed ID: 1346369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of CD11a/CD18-CD54 interactions in human T cell-dependent B cell activation.
    Tohma S; Hirohata S; Lipsky PE
    J Immunol; 1991 Jan; 146(2):492-9. PubMed ID: 1670945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergy of B cell growth factor and interleukin 2 in the proliferation of activated human B cells.
    Romagnani S; Giudizi GM; Maggi E; Almerigogna F; Biagiotti R; Del Prete G; Mazzetti M; Alessi A; Vercelli D; Ricci M
    Eur J Immunol; 1985 Dec; 15(12):1158-64. PubMed ID: 3936718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro autoantibody production by normal adult and cord blood B cells.
    Pisetsky DS; Jelinek DF; McAnally LM; Reich CF; Lipsky PE
    J Clin Invest; 1990 Mar; 85(3):899-903. PubMed ID: 2138166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of IL-2 in the generation of CD4+ suppressors of human B cell responsiveness.
    Hirohata S; Davis LS; Lipsky PE
    J Immunol; 1989 May; 142(9):3104-12. PubMed ID: 2523423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyclonal B cell activation arises from different mechanisms in lupus-prone (NZB x NZW)F1 and MRL/MpJ-lpr/lpr mice.
    Merino R; Iwamoto M; Fossati L; Izui S
    J Immunol; 1993 Dec; 151(11):6509-16. PubMed ID: 7902378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.